Spironolactone’s anti-androgen activity can lead to side effects like gynecomastia, while eplerenone, a selective aldosterone receptor antagonist, has negligible affinity for androgen and progesterone receptors, making it a more advantageous option.[1] Further research demonstrates that ACE inhibitors, ARBs, and cyclooxygenase inhibitors can also be employed in GS treatment. This evidence concerns the gene NR3C2 and Gynecomastia.